Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serum 25-hydroxyvitamin D level · people with sickle cell disease
1 finding from 1 review
Nutritional rickets‐ biochemical · term breastfed infants to prevent vitamin D deficiency and improve bone health
1 finding from 1 review
Hypercalcaemia · term breastfed infants to prevent vitamin D deficiency and improve bone health
Vitamin D given to infants showed no clear difference in adverse effect (hypercalcaemia) compared with vitamin D given to lactating mothers (low certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in all‐cause mortality (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in symptomatic catheter‐related thrombosis (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no VKA (very low certainty).
1 finding from 1 review
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in major bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in minor bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Antibiotic versus heparin only lock/flush solution: catheter‐related infections · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in catheter‐related infection (3 months) compared with no VKA (low certainty).
1 finding from 1 review
Premature CVC removal (3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in premature CVC removal (3 months) compared with no VKA (low certainty).
1 finding from 1 review
Outcomes ( · people with cancer with thrombosis prophylaxis and central venous catheters
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of dementia ‐ not measured · MCI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive function · MCI
1 finding from 1 review
Cognitive subdomain: episodic memory measured at the end of · MCI
1 finding from 1 review
Executive function (specific cognitive function) · MCI
1 finding from 1 review
Information processing speed · MCI
1 finding from 1 review
Quality of life · MCI
1 finding from 1 review
Mortality ‐ not reported · MCI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found